Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
Abstract Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC), and is frequently accompanied by the genetic features of von Hippel–Lindau (VHL) loss. VHL loss increases the expression of hypoxia-inducible factors (HIFs) and their targets, including epiderm...
Main Authors: | Yongchang Lai, Zhijian Zhao, Tao Zeng, Xiongfa Liang, Dong Chen, Xiaolu Duan, Guohua Zeng, Wenqi Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12935-018-0530-2 |
Similar Items
-
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
by: Ilaria Grazia Zizzari, et al.
Published: (2020-09-01) -
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
by: Zhichao Tian, et al.
Published: (2020-08-01) -
Axitinib as a third or further line of treatment in renal cancer: a single institution experience
by: G. Tsironis, et al.
Published: (2020-06-01) -
Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis
by: Ryota Morinaga, et al.
Published: (2019-08-01) -
Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
by: Wang H, et al.
Published: (2016-06-01)